X

Trial Profile

Efficacy of Gabapentin Enacarbil vs Placebo in Patients with Postherpetic Neuralgia and a Pharmacokinetic Comparison with Oral Gabapentin.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Aug 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gabapentin enacarbil (Primary)
Indications Neuropathic pain; Postherpetic neuralgia
Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
Sponsors XenoPort

Most Recent Events

07 Jun 2012 Results from this trial were used to support approval of gabapentin enacarbil for the treatment of postherpetic neuralgia in the US.
13 Jan 2009 GlaxoSmithKline expects results from this trial during 2009, according to a Xenoport media release.
15 Nov 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com